The Use of Amodiaquin (Camoquin) in the Treatment of Polymorphous Light Eruption

Publisher Website
Google Scholar
Abstract
The antimalarial drugs quinacrine (Atabrine), chloroquine (Aralen), and hydroxychloroquine (Plaquenil) are effective agents for the prevention and treatment of polymorphous light eruption1-6 and also for the treatment of discoid lupus erythematosus.5,7 A new antimalarial compound, amodiaquin (Camoquin), recently has been reported to be equally valuable in the treatment of discoid lupus erythematosus.8,9 The present study was done to evaluate the effectiveness of this drug in the treatment and suppression of polymorphous light eruption. Nine patients with a history of recurrent prurigo and plaque-like forms of polymorphous light eruption were studied. These patients had had recurrences of their sunlight-induced eruption each summer, for periods ranging from 6 to 23 years. The eruption had been suppressed in eight of the nine patients during the preceding three summers (1953-1955) by chloroquine. The patients were not given suppressive antimalarial therapy during the spring and early summer of 1956 and were

This publication has 0 references indexed in Scilit: